HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Ismail El-Hamamsy Michel Carrier Michel Pellerin Denis Bouchard Philippe Demers Raymond Cartier Pierre Page Louis P. Perrault Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by El-Hamamsy, I. Articles by Perrault, L. P. Search for Related Content PubMed PubMed Citation Articles by El-Hamamsy, I. Articles by Perrault, L. P. Related Collections Myocardial protection

J Thorac Cardiovasc Surg 2007;133:7-12
© 2007 The American Association for Thoracic Surgery

Cardiopulmonary Support and Physiology

Effect of intravenous N-acetylcysteine on outcomes after coronary artery bypass surgery: A randomized, double-blind, placebo-controlled clinical trial

Research Center and Department of Surgery, Montreal Heart Institute and Université de Montréal, Montreal, Quebec, Canada.

Received for publication June 8, 2005; revisions received April 25, 2006; accepted for publication May 24, 2006.

^_* Address for reprints: Louis P. Perrault, MD, PhD, Montreal Heart Institute, 5000 Bélanger St East, Montréal, Québec, H1T 1C8, Canada (Email: louis.perrault{at}icm-mhi.org).

OBJECTIVE: N-acetylcysteine, a potent anti-inflammatory and antioxidant agent, is known to decrease the production of reactive oxygen species after cardiac surgery. The objective of this study was to evaluate the effects of intravenous N-acetylcysteine on clinical and biochemical outcomes after coronary artery bypass surgery with cardiopulmonary bypass.

METHODS: One hundred patients (mean age 60.5 years, range 43-78 years, 89% male) undergoing coronary artery bypass grafting at the Montreal Heart Institute were randomized to receive either N-acetylcysteine (600 mg orally the day before and the morning of the operation, a bolus of 150 mg/kg of intravenous N-acetylcysteine before skin incision, followed by perfusion at 12.5 mg · kg^–1 · h^–1 over 24 hours; n = 50) or placebo (n = 50). The patients and clinical team were blinded to group assignments. Preoperative characteristics were similar between the two groups. Postoperative clinical data (death, myocardial infarction, low-output syndromes, arrhythmias, bleeding, transfusion requirements, and intensive care unit and hospital lengths of stay) and biochemical markers (creatine kinase MB, troponin T, creatinine, hemoglobin, and platelet levels) were evaluated serially over 4 days.

RESULTS: Clinical outcomes were not significantly different between the two groups with regard to the incidence of death, myocardial infarction, bleeding, transfusion requirements, intubation time, and hospital length of stay. No differences were found in postoperative biochemical markers (troponin T, creatine kinase MB, creatinine, hemoglobin, and platelets) between the groups. No differences were observed between the groups in interleukin-6 production (P = not significant).

CONCLUSIONS: Prophylactic use of N-acetylcysteine in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass does not lead to improvement in clinical results or biochemical markers. Further strategies to decrease reperfusion injury should be devised.

This article has been cited by other articles:

				A. S. Adabag, A. Ishani, H. E. Bloomfield, A. K. Ngo, and T. J. Wilt Efficacy of N-acetylcysteine in preventing renal injury after heart surgery: a systematic review of randomized trials Eur. Heart J., August 1, 2009; 30(15): 1910 - 1917. [Abstract] [Full Text] [PDF]

				P. Kolh Renal insufficiency after cardiac surgery: a challenging clinical problem Eur. Heart J., August 1, 2009; 30(15): 1824 - 1827. [Full Text] [PDF]

				H. Dreger, K. Westphal, A. Weller, G. Baumann, V. Stangl, S. Meiners, and K. Stangl Nrf2-dependent upregulation of antioxidative enzymes: a novel pathway for proteasome inhibitor-mediated cardioprotection Cardiovasc Res, July 15, 2009; 83(2): 354 - 361. [Abstract] [Full Text] [PDF]

				D. Bainbridge What Was Hot and What Was Not in 2007?: A Literature Review Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2009; 13(2): 78 - 80. [Abstract] [PDF]

				R. Sethi, A. Adameova, K. S. Dhalla, M. Khan, V. Elimban, and N. S. Dhalla Modification of Epinephrine-induced Arrhythmias by N-Acetyl-L-Cysteine and Vitamin E Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2009; 14(2): 134 - 142. [Abstract] [PDF]

				W. L. Baker, M. W. Anglade, E. L. Baker, C. M. White, J. Kluger, and C. I. Coleman Use of N-acetylcysteine to reduce post-cardiothoracic surgery complications: a meta-analysis Eur. J. Cardiothorac. Surg., March 1, 2009; 35(3): 521 - 527. [Abstract] [Full Text] [PDF]

				S. U. Nigwekar and P. Kandula N-Acetylcysteine in Cardiovascular-Surgery-Associated Renal Failure: A Meta-Analysis Ann. Thorac. Surg., January 1, 2009; 87(1): 139 - 147. [Abstract] [Full Text] [PDF]

				M. Ozaydin, O. Peker, D. Erdogan, S. Kapan, Y. Turker, E. Varol, F. Ozguner, A. Dogan, and E. Ibrisim N-acetylcysteine for the prevention of postoperative atrial fibrillation: a prospective, randomized, placebo-controlled pilot study Eur. Heart J., March 1, 2008; 29(5): 625 - 631. [Abstract] [Full Text] [PDF]

				D. J. Chambers Oxidative stress injury during cardiac surgery: How important is it? Cardiovasc Res, March 1, 2007; 73(4): 626 - 628. [Full Text] [PDF]